The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Tesla, Inc. (TSLA), The Home Depot, ...

Learn more about whether Alvotech or Twist Bioscience Corporation is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

The business is notable for its commitment to rare diseases; it has successfully introduced eight innovative medications to the market, including therapies for lysosomal storage diseases ...

Unity Biotechnology’s investigational eye treatment failed to match Eylea at 20 weeks—part of the mid-stage trial’s primary endpoint and the only time stamp out of 10 in which the candidate ...

Now, the candidate has failed to match Eylea in a phase 3 trial, leaving the Australian biotech to consider its own future. The drug in question is sozinibercept, an inhibitor of vascular ...

had infringed on U.S. Patent 11,084,865, claimed to cover a vial containing Eylea. As a result of the ruling, Amgen, which produces a biosimilar for Eylea, saw its shares increase by as much as 0.5%.

An appeals court has upheld a District Court’s denial of a preliminary injunction for Amgen’s (AMGN) Eylea biosimilar, which UBS analyst Trung Huynh tells investors in “negative, but ...

Having said that, Tesla's long-term growth prospects remain strong, driven by its thriving Energy Generation & Storage segment, expansive Supercharger network and AI advancements. Tesla’s robust ...

This arrangement, the lawsuit claims, effectively lowered Eylea's selling price and provided Regeneron with a competitive advantage in the anti-VEGF medication market. The Department of Justice ...